IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v7y2010i8p3150-3195d9220.html
   My bibliography  Save this article

Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases

Author

Listed:
  • Sanjib Saha

    (Centre for Primary Health Care Research, Lund University, Lund, Sweden
    Health Economics & Management, Institute of Economic Research, Lund University, Lund, Sweden)

  • Ulf-G Gerdtham

    (Centre for Primary Health Care Research, Lund University, Lund, Sweden
    Health Economics & Management, Institute of Economic Research, Lund University, Lund, Sweden
    Department of Economics, Lund University, Lund, Sweden)

  • Pia Johansson

    (Division of Public Health Epidemiology, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden)

Abstract

Lifestyle interventions ( i.e. , diet and/or physical activity) are effective in delaying or preventing the onset of diabetes and cardiovascular disease. However, policymakers must know the cost-effectiveness of such interventions before implementing them at the large-scale population level. This review discusses various issues (e.g., characteristics, modeling, and long-term effectiveness) in the economic evaluation of lifestyle interventions for the primary and secondary prevention of diabetes and cardiovascular disease. The diverse nature of lifestyle interventions, i.e. , type of intervention, means of provision, target groups, setting, and methodology, are the main obstacles to comparing evaluation results. However, most lifestyle interventions are among the intervention options usually regarded as cost-effective. Diabetes prevention programs, such as interventions starting with targeted or universal screening, childhood obesity prevention, and community-based interventions, have reported favorable cost-effectiveness ratios.

Suggested Citation

  • Sanjib Saha & Ulf-G Gerdtham & Pia Johansson, 2010. "Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases," IJERPH, MDPI, vol. 7(8), pages 1-46, August.
  • Handle: RePEc:gam:jijerp:v:7:y:2010:i:8:p:3150-3195:d:9220
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/7/8/3150/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/7/8/3150/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. E. T. Ronckers & W. Groot & A.J.H.A. Ament, 2005. "Systematic Review of Economic Evaluations of Smoking Cessation: Standardizing the Cost-Effectiveness," Medical Decision Making, , vol. 25(4), pages 437-448, July.
    2. Alan Brennan & Roberta Ara & Raimund Sterz & Bernd Matiba & Rito Bergemann, 2006. "Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(4), pages 276-284, December.
    3. David Eddy, 2006. "Accuracy versus Transparency in Pharmacoeconomic Modelling," PharmacoEconomics, Springer, vol. 24(9), pages 837-844, September.
    4. Moodie, Marjory & Haby, Michelle & Wake, Melissa & Gold, Lisa & Carter, Robert, 2008. "Cost-effectiveness of a family-based GP-mediated intervention targeting overweight and moderately obese children," Economics & Human Biology, Elsevier, vol. 6(3), pages 363-376, December.
    5. Rob Anderson, 2010. "Systematic reviews of economic evaluations: utility or futility?," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 350-364, March.
    6. Emma Warren & Alan Brennan & Ron Akehurst, 2004. "Cost-Effectiveness of Sibutramine in the Treatment of Obesity," Medical Decision Making, , vol. 24(1), pages 9-19, January.
    7. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
    8. Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
    9. Lois G. Kim & Simon G. Thompson, 2010. "Uncertainty and validation of health economic decision models," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 43-55, January.
    10. Carmen Galani & Heinz Schneider & Frans Rutten, 2007. "Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 52(6), pages 372-382, December.
    11. Salkeld, Glenn & Phongsavan, Philayrath & Oldenburg, Brian & Johannesson, Magnus & Convery, Paula & Graham-Clarke, Peita & Walker, Sheila & Shaw, John, 1997. "The cost-effectiveness of a cardiovascular risk reduction program in general practice," Health Policy, Elsevier, vol. 41(2), pages 105-119, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Vicky Van Stappen & Julie Latomme & Greet Cardon & Ilse De Bourdeaudhuij & Mina Lateva & Nevena Chakarova & Jemina Kivelä & Jaana Lindström & Odysseas Androutsos & Esther González-Gil & Pilar De Migue, 2018. "Barriers from Multiple Perspectives Towards Physical Activity, Sedentary Behaviour, Physical Activity and Dietary Habits When Living in Low Socio-Economic Areas in Europe. The Feel4Diabetes Study," IJERPH, MDPI, vol. 15(12), pages 1-15, December.
    2. Nobutaka Hirooka & Takeru Kusano & Shunsuke Kinoshita & Hidetomo Nakamoto, 2021. "Influence of Perceived Stress and Stress Coping Adequacy on Multiple Health-Related Lifestyle Behaviors," IJERPH, MDPI, vol. 19(1), pages 1-9, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ulla K. Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    2. Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    3. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    4. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    5. Sanjib Saha & Katarina Steen Carlsson & Ulf-G Gerdtham & Margareta K Eriksson & Lars Hagberg & Mats Eliasson & Pia Johansson, 2013. "Are Lifestyle Interventions in Primary Care Cost-Effective? – An Analysis Based on a Markov Model, Differences-In-Differences Approach and the Swedish Björknäs Study," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-1, November.
    6. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Management of Dementia Patients - A Systematic Literature Review," Working Papers 2018:41, Lund University, Department of Economics.
    7. Nora Döring & Susanne Mayer & Finn Rasmussen & Diana Sonntag, 2016. "Economic Evaluation of Obesity Prevention in Early Childhood: Methods, Limitations and Recommendations," IJERPH, MDPI, vol. 13(9), pages 1-11, September.
    8. Mandana Zanganeh & Peymane Adab & Bai Li & Emma Frew, 2019. "A Systematic Review of Methods, Study Quality, and Results of Economic Evaluation for Childhood and Adolescent Obesity Intervention," IJERPH, MDPI, vol. 16(3), pages 1-14, February.
    9. Ryuichi Ohta & Yoshinori Ryu & Daisuke Kataoka & Chiaki Sano, 2021. "Effectiveness and Challenges in Local Self-Governance: Multifunctional Autonomy in Japan," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
    10. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    11. Scott Metcalfe & Rachel Grocott, 2010. "Comments on “Simoens, S. Health Economic Assessment: A Methodological Primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966”—New Zealand in Fact Has No Cost-Effectiveness Threshold," IJERPH, MDPI, vol. 7(4), pages 1-4, April.
    12. Marieke Krol & Jocé Papenburg & Siok Swan Tan & Werner Brouwer & Leona Hakkaart, 2016. "A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(4), pages 391-402, May.
    13. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    14. Anna Nicolet & Antoinette D I van Asselt & Karin M Vermeulen & Paul F M Krabbe, 2020. "Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    15. Nikolai Mühlberger & Gaby Sroczynski & Artemisa Gogollari & Beate Jahn & Nora Pashayan & Ewout Steyerberg & Martin Widschwendter & Uwe Siebert, 2021. "Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(8), pages 1311-1344, November.
    16. Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk, 2015. "Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany," PharmacoEconomics, Springer, vol. 33(11), pages 1215-1228, November.
    17. Garattini, Livio & van de Vooren, Katelijne & Curto, Alessandro, 2015. "Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?," Health Policy, Elsevier, vol. 119(2), pages 212-216.
    18. Klingler, Corinna & Shah, Sara M.B. & Barron, Anthony J.G. & Wright, John S.F., 2013. "Regulatory space and the contextual mediation of common functional pressures: Analyzing the factors that led to the German Efficiency Frontier approach," Health Policy, Elsevier, vol. 109(3), pages 270-280.
    19. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
    20. S. Rajsic & H. Gothe & H. H. Borba & G. Sroczynski & J. Vujicic & T. Toell & Uwe Siebert, 2019. "Economic burden of stroke: a systematic review on post-stroke care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 107-134, February.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:7:y:2010:i:8:p:3150-3195:d:9220. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.